LONDON, June 23, 2011 /PRNewswire/ --
Pharma IQ has just published the results of an Industry-wide Bioequivalence and Bioavailability Survey, conducted recently among 2,000 bioequivalence and bioavailability experts.
The results showed that 33.3% of respondents found the ability
to secure biowaivers as their main concern; another third said it
was validating IVIVC. Two-thirds of the respondents said that the
most important factor when choosing a service provider was a strong
working relationship. Only a third of companies were more concerned
by the upfront cost, while a CRO's reputation alone would not be
enough to sway any of the participants.
With regard to the satisfaction with their current service providers, 66.7% of companies would not rush to change service provider while the remaining third claimed to be not entirely pleased with their partner's offering.
The survey was created as a part of the pre-conference research for 2nd Annual Bioequivalence and Bioavailability Studies, taking place 19-20 September, 2011 in Brussels. The results helped to shape the agenda and the final speaker line-up which features AGES providing the delegates with an overview of current guidelines and National Institute for Pharmacy Directorate from Hungary sharing a regulatory perspective on the EMA bioequivalence guideline one year on. BfArM will outline the EU guideline on the validation of bioanalytical methods.
Other important topics expressed by survey respondents and will be discussed at the event include:
To access the full survey report or to find out more about Bioequivalence and Bioavailability Studies 2011 please visit Bioequivalence and Bioavailability page, email firstname.lastname@example.org or call +44(0)2073689421
Media contact: Joanna Checinska, +44(0)20-7368-9421, email@example.com - Please contact for more information or images.
Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Joanna Checinska (firstname.lastname@example.org)
|SOURCE Pharma IQ|
Copyright©2010 PR Newswire.
All rights reserved